Conclusions: Resmetirom and FGF21 show promise in treating MASLD and MASH, with Resmetirom particularly effective in reducing liver fat and improving liver enzymes. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.